Document Detail


The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
MedLine Citation:
PMID:  6361300     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a 19% lower incidence of coronary heart disease (CHD) in cholestyramine-treated men was accompanied by mean falls of 8% and 12% in plasma total (TOTAL-C) and low-density lipoprotein (LDL-C) cholesterol levels relative to levels in placebo-treated men. When the cholestyramine treatment group was analyzed separately, a 19% reduction in CHD risk was also associated with each decrement of 8% in TOTAL-C or 11% in LDL-C levels (P less than .001). Moreover, CHD incidence in men sustaining a fall of 25% in TOTAL-C or 35% in LDL-C levels, typical responses to the prescribed dosage (24 g/day) of cholestyramine resin, was half that of men who remained at pretreatment levels. Adherence to medication was associated with reduced incidence of CHD only when accompanied by falls in TOTAL-C and LDL-C levels. Small increases in high-density lipoprotein cholesterol levels, which accompanied cholestyramine treatment, independently accounted for a 2% reduction in CHD risk. Thus, the reduction of CHD incidence in the cholestyramine group seems to have been mediated chiefly by reduction of TOTAL-C and LDL-C levels.
Authors:
-
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  JAMA     Volume:  251     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  1984 Jan 
Date Detail:
Created Date:  1984-02-22     Completed Date:  1984-02-22     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  365-74     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cholesterol / blood*
Cholesterol, HDL
Cholesterol, LDL
Cholestyramine Resin / therapeutic use*
Clinical Trials as Topic
Coronary Disease / blood,  epidemiology,  prevention & control*
Dose-Response Relationship, Drug
Double-Blind Method
Humans
Hypercholesterolemia / drug therapy
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Male
Grant Support
ID/Acronym/Agency:
N01-HV1-2156-L/HV/NHLBI NIH HHS; N01-HV1-2160-L/HV/NHLBI NIH HHS; N01-HV2-2914-L/HV/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 11041-12-6/Cholestyramine Resin; 97C5T2UQ7J/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of c...
Next Document:  Comprehensive evaluation of cefotetan in pediatrics